Product Description
Bazedoxifene is an indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration, bazedoxifene specifically binds to estrogen receptors in responsive tissues, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it either promotes or suppresses the transcription of estrogen-regulated genes. Bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bazedoxifene)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Mexico | New Zealand | Norway | Poland | Portugal | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States
Approved Indications: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|COVID-19|Ductal Breast Carcinoma|Ductal Carcinoma|Intraductal Noninfiltrating Carcinoma|Pneumonia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02694809 |
The PROMISE Study | P2 |
Completed |
Ductal Breast Carcinoma|Breast Cancer|Ductal Carcinoma|Intraductal Noninfiltrating Carcinoma |
2024-06-19 |
2025-02-07 |
Primary Endpoints|Treatments |
|
2021-005247-78 |
2021-005247-78 | P2 |
Active, not recruiting |
Pneumonia|COVID-19 |
2023-01-19 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/18/2025 |
News Article |
Hormone Therapy Market to Reach USD 41.97 Billion by 2035, Growing at 7.20% CAGR |
|
09/26/2023 |
News Article |
Atmosic to Launch New Mobile App Viviant, Developed by Fusionary, to Help Companies Quickly Test and Evaluate Atmosic's Wireless Platforms for the IoT |
|
09/14/2023 |
News Article |
[2023-2030] Alternative Fuels Advisor Market Size, Trending Report |
|
09/09/2023 |
News Article |
Alternative Fuels Advisor Market 2023 Report Covers Future Trends with Research Forecast till 2031 |